Start Your Search
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
P2.01-072 - Local Management of Oligometastasis in Non-Small Cell Lung Cancer (NSCLC) (ID 10104)
09:00 - 16:00 | Author(s): J.C. Trujillo
Stage IV NSCLC patients with oligometastasis may experience long-term survival when macroscopic tumour sites are treated radically. The aim of this abstract is to analyse our experience in local management of oligometastasis in NSCLC.
We retrospectively analysed 38 patients with oligometastatic NSCLC in terms of overall survival (OS), progression-free survival from diagnosis (SLP) and treatment (SLPT) of oligometastatic disease and the association with clinical features such as age, gender, histology, molecular profile, stage at diagnosis and metastatic sites. Kaplan Meier method was used.
We analysed 38 patients (25 men, 13 women). Mean age: 61 years (40-82). Histology: 60% adenocarcinoma, 8% squamous carcinoma, 13% large cell carcinoma, 19% NOS. 2 EGFR and 1 BRAF mutations. 60% patients (23/38) presented oligometastatic NSCLC at diagnosis, 34% after progression of early disease and 6% after response to initial systemic treatment for advanced disease. Mean number of metastasis: 1 (1-3). Most frequent location: brain (80%). 35% of patients (8/23) oligometastatic at diagnosis received local treatment for the primary tumour: 75% surgery, 25% radiotherapy. Systemic therapy was administrated in 65% of patients (15/23): 93% platinum-based chemotherapy, 7% EGFR-TKI. Table 1 shows local treatment for oligometastasis at diagnosis. No severe complications were observed.
With a median follow up of 23 months (95%CI 0.9-78.2m), median SLPT was 8.5 months (95%CI 5.3-11.7m), median SLP was 8.7 months (95%CI 6.1 – 11.3m) and median OS was 9.9 months (95%CI 0-32). Median OS of brain metastasis was 9.7 months (95%CI 6.5-12m) vs not reached in patients without brain metastasis (p 0.019). Median OS patients with oligometastatic NSCLC at diagnosis was 8.7 months (95%CI 5'9-11) vs not reached in the rest of patients (p 0.025).
Table 1 Brain (n=30, 80%) Adrenal gland (n=4, 10%) Lung (n=3, 8%) Liver (n=1, 2%) Surgery + Radiotherapy 87% (26/30) Surgery 10% (3/30) 50% (2/4) 67% (2/3) Radiotherapy 33% (1/3) No local treatment 3% (1/30) 50% (2/4) 100% (1/1)
Data collected demonstrate that survival rate in patients with oligometastatic NSCLC is similar to that reported in literature. Cerebral metastasis significantly worsen the prognosis.